At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SLXN Silexion Therapeutics Corp
Not Yet Opened 09-21 16:00:00 EDT
0.5441
+0.1086
+24.94%
盘后0.5523
+0.0082+1.51%
19:59 EDT
High0.6303Low0.4149Vol20.13M
Open0.4200D1 Closing0.4355Amplitude49.47%
Mkt Cap3.13MTradable Cap3.09MTotal Shares5.76M
T/O10.28MT/O Rate354.85%Tradable Shares5.67M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences
GlobeNewswire  ·  09-09
Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences
After Moderna’s $44B Oncology Win, Silexion’s Pancreatic Cancer Treatment is Worth Exploring (NASDAQ: SLXN)
TIPRANKS  ·  08-25
After Moderna’s $44B Oncology Win, Silexion’s Pancreatic Cancer Treatment is Worth Exploring (NASDAQ: SLXN)
Silexion Therapeutics Announces Extraordinary Shareholder Meeting
Reuters  ·  08-25
Silexion Therapeutics Announces Extraordinary Shareholder Meeting
Silexion Therapeutics Faces NASDAQ Delisting Notice over Minimum Shareholders’ Equity Shortfall
Reuters  ·  08-22
Silexion Therapeutics Faces NASDAQ Delisting Notice over Minimum Shareholders’ Equity Shortfall
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Atai Beckley N.V. (ATAI), InspireMD (NSPR) and Silexion Therapeutics (SLXN)
TIPRANKS  ·  08-20
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Atai Beckley N.V. (ATAI), InspireMD (NSPR) and Silexion Therapeutics (SLXN)
Silexion Therapeutics Announces Extraordinary General Meeting
Reuters  ·  08-15
Silexion Therapeutics Announces Extraordinary General Meeting
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
THOMSON REUTERS  ·  08-14
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte
Reuters  ·  08-13
U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte
Top Premarket Decliners
MT Newswires Live  ·  08-12
Top Premarket Decliners
Silexion Therapeutics Prices USD 2.5 Million Public Offering at USD 0.65 Per Share with Warrants
Reuters  ·  08-12
Silexion Therapeutics Prices USD 2.5 Million Public Offering at USD 0.65 Per Share with Warrants
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering
THOMSON REUTERS  ·  08-12
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering
Immunotherapy’s Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN)
TIPRANKS  ·  08-11
Immunotherapy’s Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN)
Silexion Therapeutics Publishes Corporate Deck Spotlighting Sil204 siRNA Program Targeting KRAS-Driven Cancers
Reuters  ·  08-09
Silexion Therapeutics Publishes Corporate Deck Spotlighting Sil204 siRNA Program Targeting KRAS-Driven Cancers
Silexion Therapeutics files to sell ordinary shares, warrants, no amount given
TIPRANKS  ·  08-08
Silexion Therapeutics files to sell ordinary shares, warrants, no amount given
Silexion Reports Preclinical Sil204 Data Supporting Phase 2/3 Development in KRAS-Driven Cancers
Reuters  ·  08-04
Silexion Reports Preclinical Sil204 Data Supporting Phase 2/3 Development in KRAS-Driven Cancers
Silexion Therapeutics Corp - Announces Positive Preclinical Findings for Sil204 in Kras-Mutant Cancer Cells
THOMSON REUTERS  ·  08-04
Silexion Therapeutics Corp - Announces Positive Preclinical Findings for Sil204 in Kras-Mutant Cancer Cells
Silexion Therapeutics Director Amnon Peled Resigns for Personal Reasons
Reuters  ·  08-01
Silexion Therapeutics Director Amnon Peled Resigns for Personal Reasons
Silexion Activates First Site in Phase 2/3 Trial Targeting KRAS-Driven Pancreatic Cancer (NASDAQ: SLXN)
TIPRANKS  ·  07-29
Silexion Activates First Site in Phase 2/3 Trial Targeting KRAS-Driven Pancreatic Cancer (NASDAQ: SLXN)
Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of Sil204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center
THOMSON REUTERS  ·  07-29
Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of Sil204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center
Silexion Therapeutics Corp - Additional Israeli and German Sites Expected to Join Sil204 Phase 2/3 Trial in Coming Months
THOMSON REUTERS  ·  07-29
Silexion Therapeutics Corp - Additional Israeli and German Sites Expected to Join Sil204 Phase 2/3 Trial in Coming Months

Introduction

Company Name.
Silexion Therapeutics Corp
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Moringa Acquisition Corp does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company focuses on pursuing opportunities in technology-based businesses or industries in Israel. Moringa Acquisition Corp was incorporated in 2020 and is based in New York, New York.
Issue price:
--